Previous close | 8.46 |
Open | 9.12 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 8.46 - 8.46 |
52-week range | 7.46 - 15.80 |
Volume | |
Avg. volume | 2,051 |
Market cap | 5.567B |
Beta (5Y monthly) | 0.68 |
PE ratio (TTM) | 84.60 |
EPS (TTM) | 0.10 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 03 Jun 2021 |
1y target est | N/A |
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.
Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday. Grifols did not specify the amount due next year. Since January, the Spanish drug maker's debt sustainability has been questioned by short seller Gotham City Research.